^
    Back
    Association details:
    Biomarker:PIK3CA E545K
    Cancer:HER2 Negative Breast Cancer
    Drug:CYH33 (PIK3CA inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Nat Commun
    Title:

    First-in-human phase Ia study of the PI3Kα inhibitor CYH33 in patients with solid tumors

    Published date:
    11/16/2022
    Excerpt:
    One of the patients in the 40 mg CYH33 treatment group, a 45-year-old female with breast cancer (Luminal B, HER2-, PIK3CA E545K mutation), had a rapid and remarkable response to CYH33...On the Cycle 1 Day 8 (C1D8) visit of CYH33 treatment, the patient experienced visible shrinkage and necrosis of the right breast mass, and the necrotic mass disappeared on the C1D15 visit.
    DOI:
    10.1038/s41467-022-34782-9
    Trial ID:
    NCT03544905